Cited by 240

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01

Piao, Jinghua, Zabierowski, Susan, Dubose, Brittany N., Hill, Ellen J., Navare, Monalisa, Claros, Nidia, Rosen, Siera, Ramnarine, Kiran, Horn, Callie, Fredrickson, Craig, Wong, Karen, Safford, Brent, Kriks, Sonja, El Maarouf, Abderrahman, Rutishauser, Urs, Henchcliffe, Claire, Wang, Yongzeng, Riviere, Isabelle, Mann, Shannon, Bermudez, Vladimir, Irion, Stefan, Studer, Lorenz, Tomishima, Mark, Tabar, Viviane·2021·Cell Stem Cell

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.stem.2021.01.004

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The absence of GID in this study through 18 months may relate to the lack of serotonergic neuron contaminants in bemdaneprocel.

    “The absence of GID in our study through 18 months is therefore particularly notable. This may relate to the lack of serotonergic neuron contaminants in bemdaneprocel, as preclinical studies confirmed the absence of serotonergic neurons in vitro and in vivo at 9 months after grafting34.”

    From Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease (2025) · cites this paper as [34]

    In Results and discussion, the Parkinsonian-rat graft analysis reports negative 5-HT staining, suggesting an absence of human serotonergic neurons in vivo. The cited paper does not establish their absence in vitro; its separate graft follow-up extends to day 266. The proposed link to the citing study’s absence of GID is the citing authors’ inference, not a finding attributed to this preclinical paper. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Preclinical studies confirmed the absence of serotonergic neurons in bemdaneprocel in vitro and in vivo at 9 months after grafting.

    “The absence of GID in our study through 18 months is therefore particularly notable. This may relate to the lack of serotonergic neuron contaminants in bemdaneprocel, as preclinical studies confirmed the absence of serotonergic neurons in vitro and in vivo at 9 months after grafting34.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 30

  1. Barker, 2019, Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease, Nat. Med., 25, 1045, 10.1038/s41591-019-0507-2 · DOI · Paper page
  2. Brown, 2017, Practical Stereology Applications for the Pathologist, Vet. Pathol., 54, 358, 10.1177/0300985817695781 · DOI
  3. Cyranoski, 2018, ‘Reprogrammed’ stem cells implanted into patient with Parkinson’s disease, Nat. News, 10.1038/d41586-018-07407-9 · DOI
  4. Deng, 2011, Specific and integrated roles of Lmx1a, Lmx1b and Phox2a in ventral midbrain development, Development, 138, 3399, 10.1242/dev.065482 · DOI
  5. Doi, 2020, Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson’s disease, Nat. Commun., 11, 3369, 10.1038/s41467-020-17165-w · DOI · Paper page
  6. Ferri, 2007, Foxa1 and Foxa2 regulate multiple phases of midbrain dopaminergic neuron development in a dosage-dependent manner, Development, 134, 2761, 10.1242/dev.000141 · DOI
  7. Freed, 2001, Transplantation of embryonic dopamine neurons for severe Parkinson’s disease, N. Engl. J. Med., 344, 710, 10.1056/NEJM200103083441002 · DOI · Paper page
  8. Freed, 2011, Dopamine cell transplantation for Parkinson’s disease: the importance of controlled clinical trials, Neurotherapeutics, 8, 549, 10.1007/s13311-011-0082-9 · DOI
  9. Gardi, 2008, The proportionator: unbiased stereological estimation using biased automatic image analysis and non-uniform probability proportional to size sampling, Comput. Biol. Med., 38, 313, 10.1016/j.compbiomed.2007.11.002 · DOI
  10. Gundersen, 1986, Stereology of arbitrary particles. A review of unbiased number and size estimators and the presentation of some new ones, in memory of William R. Thompson, J. Microsc., 143, 3, 10.1111/j.1365-2818.1986.tb02764.x · DOI
  11. Kadkhodaei, 2009, Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons, J. Neurosci., 29, 15923, 10.1523/JNEUROSCI.3910-09.2009 · DOI · Paper page
  12. Kim, 2021, Biphasic activation of WNT signaling enhances the derivation of midbrain dopamine neurons for translational use, Cell Stem Cell, 28, 343, 10.1016/j.stem.2021.01.005 · DOI · Paper page
  13. Kordower, 1995, Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease, N. Engl. J. Med., 332, 1118, 10.1056/NEJM199504273321702 · DOI
  14. Kriks, 2011, Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease, Nature, 480, 547, 10.1038/nature10648 · DOI
  15. Krystkowiak, 2007, Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington’s disease, PLoS ONE, 2, e166, 10.1371/journal.pone.0000166 · DOI
  16. Lanza, 2019, Engineering universal cells that evade immune detection, Nat. Rev. Immunol., 19, 723, 10.1038/s41577-019-0200-1 · DOI
  17. Li, 2016, Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain, Proc. Natl. Acad. Sci. U S A, 113, 6544, 10.1073/pnas.1605245113 · DOI · Paper page
  18. Liedtke, 2007, Oct4 and its pseudogenes confuse stem cell research, Cell Stem Cell, 1, 364, 10.1016/j.stem.2007.09.003 · DOI
  19. Mendez, 2005, Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson’s disease, Brain, 128, 1498, 10.1093/brain/awh510 · DOI
  20. Morizane, 2013, Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate, Stem Cell Reports, 1, 283, 10.1016/j.stemcr.2013.08.007 · DOI
  21. Morizane, 2017, MHC matching improves engraftment of iPSC-derived neurons in non-human primates, Nat. Commun., 8, 385, 10.1038/s41467-017-00926-5 · DOI · Paper page
  22. Ohyama, 2005, Directed differentiation of neural cells to hypothalamic dopaminergic neurons, Development, 132, 5185, 10.1242/dev.02094 · DOI
  23. Olanow, 2003, A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease, Ann. Neurol., 54, 403, 10.1002/ana.10720 · DOI · Paper page
  24. Parmar, 2020, The future of stem cell therapies for Parkinson disease, Nat. Rev. Neurosci., 21, 103, 10.1038/s41583-019-0257-7 · DOI
  25. Perrier, 2004, Derivation of midbrain dopamine neurons from human embryonic stem cells, Proc. Natl. Acad. Sci. U S A, 101, 12543, 10.1073/pnas.0404700101 · DOI
  26. Simon, 2001, Fate of midbrain dopaminergic neurons controlled by the engrailed genes, J. Neurosci., 21, 3126, 10.1523/JNEUROSCI.21-09-03126.2001 · DOI
  27. Smidt, 2004, Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3, Development, 131, 1145, 10.1242/dev.01022 · DOI
  28. Tiklová, 2020, Single cell transcriptomics identifies stem cell-derived graft composition in a model of Parkinson’s disease, Nat. Commun., 11, 2434, 10.1038/s41467-020-16225-5 · DOI
  29. van den Munckhof, 2003, Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons, Development, 130, 2535, 10.1242/dev.00464 · DOI
  30. Williams, 2012, The cell cycle and cancer, J. Pathol., 226, 352, 10.1002/path.3022 · DOI

Cited by

Sorted by citations

Metadata

Authors
Piao, J., Zabierowski, S., Dubose, B. N., Hill, E. J., Navare, M., Claros, N., Rosen, S., Ramnarine, K., Horn, C., Fredrickson, C., Wong, K., Safford, B., Kriks, S., El Maarouf, A., Rutishauser, U., Henchcliffe, C., Wang, Y., Riviere, I., Mann, S., Bermudez, V., Irion, S., Studer, L., Tomishima, M., & Tabar, V.
Venue
Cell Stem Cell
Publisher
Elsevier BV
Published
2021-02
Volume
28
Issue
2
Pages
217-229.e7
ISSN
1934-5909
Cited by
240
References
1
Language
en
Funders
New York State Stem Cell Science (C028503, C029153)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review